TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01252186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 91-day Levonorgestrel Oral Contraceptive
Description: 91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 28-day Levonorgestrel Oral Contraceptive
Description: 21 combination tablets containing 150 µg LNG/30 µg EE.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 28-day Desogestrel Oral Contraceptive
Description: 21 combination tablets containing 150 µg DSG/30 µg EE.
Study: NCT01510366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Salk strains)
Description: Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
Study: NCT02407340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: 40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
Study: NCT04074694

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sialoendoscopy
Description: Sialoendoscopy
Study: NCT02533986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry peel drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control drink
Study: NCT03117374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team Nutriathlon intervention
Description: 8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
Study: NCT00500058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-485232
Description: SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 will be administered by IV infusion.
Study: NCT03475706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solabegron immediate release tablets, low dose
Description: twice daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solabegron immediate release tablets, high dose
Description: twice daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: twice daily for 12 weeks.
Study: NCT03630991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edetate Calcium Disodium
Description: Given IV

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succimer
Description: Given PO
Study: NCT04219553

Intervention type: OTHER
Group type: OTHER
Intervention: Comparator (no intervention)
Description: No active intervention
Study: NCT03598985

Intervention type: DIAGNOSTIC_TEST
Intervention: Smartphone MyAnkle balance application
Description: Balance will be assessed simultaneously using MyAnkle application and the Biodex balance system. The smartphone will be fixed to the middle of the shin with an armband. Participants will assume a single leg stance on each side under two conditions: eyes opened and closed. Testing will be done at three levels of difficulty; least difficult (level 8), moderate (level 6) and severe difficult (level 4). A conditioning trial for each level will be given for 30 seconds. Further, a 2-minute rest between tests will be given. During the testing, participants should not touch the ground or stance limb by other limb nor to grasp the handrail. Participants will repeat the same testing in two separate sessions, with one-week interval in between.
Study: NCT02305017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 50 mg
Study: NCT03671967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Description: 4.5 grams QID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 1 gram TID
Study: NCT02305017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol 1g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol 1g
Study: NCT02302092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flomoxef
Description: Flomoxef intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime
Description: Cefepime intravenous infusion
Study: NCT06657092

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Single-shot ultrasound (US)-guided ESP block with 20 ml 0.25% bupivacaine ( Marcaine ) at the T4 vertebral level will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standart therapy
Description: Postoperative 0.5 mg/kg morphine and 1 gr paracetamol will be admistered intravenously in the operation theatre and intravenous patient controlled analgesia (PCA) will be performed in the plastic surgery ward postoperatively
Study: NCT03296137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tumor-infiltrating lymphocytes
Description: Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: One treatment with ipilimumab (3 mg/kg) prior to tumor resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: proleukin
Description: 2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2 doses (60 mg/kg) prior to TIL infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludara
Description: 5 doses (25 mg/m2) prior to TIL infusion
Study: NCT03970226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Phase 0: One dose of tocilizumab prior to surgery~Feasibility phase: Tocilizumab administered every 2 weeks for up to 13 cycles (approximately 1 year).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Phase 0: One dose of tocilizumab prior to surgery~Feasibility phase: Tocilizumab administered every 2 weeks for up to 13 cycles (approximately 1 year).
Study: NCT02103361

Intervention type: DRUG
Intervention: Ustekinumab

Intervention type: DRUG
Intervention: Guselkumab
Study: NCT05119491

Intervention type: DEVICE
Intervention: uitrasonography and spirometry
Description: chest uitrasonography and spirometry

Intervention type: DEVICE
Intervention: uitrasonography and spirometry
Description: chest uitrasonography and spirometry
Study: NCT01784068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib followed by treatment-free
Description: Nilotinib is being used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. Treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
Study: NCT02659930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: liposomal doxorubicin IV day 1 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: liposomal doxorubicin IV day 1 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: liposomal doxorubicin IV day 1 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: liposomal doxorubicin IV day 1 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: pomalidomide once a day, days 1-21 of a 28-day cycle, at the dose levels described in dose escalation plan
Study: NCT03407144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone/prednisolone
Description: 60 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~40 mg/m\^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bleomycin
Description: 10 units/m\^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 125 mg/m\^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: RT administered daily, dose dependent on randomization group and disease response.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: RT administered daily, dose dependent on randomization group and disease response.
Study: NCT04456413

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Patients will receive best supportive care. Patients randomized to this arm may receive plasma should they require hospitalization for progression of COVID-19 disease.
Study: NCT02021396

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization
Description: this arm of the study was interventional (splenic artery embolization)
Study: NCT00146172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272
Study: NCT00210106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablathermy
Study: NCT03791216

Intervention type: OTHER
Intervention: Fasting blood draw for lipid assessments
Description: Fasting blood draw for lipid assessments

Intervention type: OTHER
Intervention: Fasting blood draw for lipid assessments
Description: Fasting blood draw for lipid assessments

Intervention type: OTHER
Intervention: Fasting blood draw for lipid assessments
Description: Fasting blood draw for lipid assessments

Intervention type: OTHER
Intervention: Fasting blood draw for lipid assessments
Description: Fasting blood draw for lipid assessments
Study: NCT04625270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766)
Description: avutometinib (VS-6766) monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766)
Description: avutometinib (VS-6766) monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and defactinib
Description: avutometinib (VS-6766) and defactinib combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and defactinib
Description: avutometinib (VS-6766) and defactinib combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and defactinib
Description: avutometinib (VS-6766) and defactinib combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and defactinib
Description: avutometinib (VS-6766) and defactinib combination
Study: NCT05216029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: View oncology dashboard

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06104384

Intervention type: BEHAVIORAL
Intervention: Behavioral and supportive therapy
Description: Behavioral and supportive therapy
Study: NCT01723592

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Probiotics oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains,L.rhamnosus/ LbV96 (DSM 22560),L.jensenii /LbV 116 (DSM 22567),L.crispatus/ Lbv88 (DSM 22566),L.gasseri /LbV 150N (DSM 22583)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral lactose placebo
Description: Placebo
Study: NCT00838461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSD-016
Study: NCT00439842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Failure Group Clinic Appointments
Description: Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
Study: NCT04021940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULOD
Description: ULOD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ULOD
Description: ULOD
Study: NCT02656979

Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost
Description: Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
Study: NCT02669732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8500a
Description: tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets
Study: NCT00967772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftopidil
Description: 25mg/ 50 mg/ 75mg dosage tablets
Study: NCT02354989

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate Response on first (VVI biventricular pacing)
Description: Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate Response off first (VVI biventricular pacing)
Description: Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
Study: NCT00587639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS Treatment
Description: Active rTMS treatment.
Study: NCT01832987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-trimoxazole
Description: On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
Study: NCT02877420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Technical Skills Training Curriculum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Simulation Training Group
Study: NCT03344250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR BATs with TMZ following SOC RT/TMZ
Description: Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly EGFR BATs following SOC RT/TMZ
Description: Standard of care: 6 weeks of RT and TMZ Experimental: 8 weekly doses of EGFR BATs following SOC RT and TMZ
Study: NCT03054389

Intervention type: OTHER
Intervention: Qualitative Interview - Participants/ Patients
Description: Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients

Intervention type: OTHER
Intervention: Qualitative Interview - Investigators and Study Coordinators
Description: Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
Study: NCT00697762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ-333369
Description: 200 mg tablet twice daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RWJ-333369
Description: 100 mg tablet twice daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily for 12 weeks
Study: NCT03530098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BoneAgeModel
Description: BoneAgeModel is an Artificial Intelligence tool that takes in a hand radiograph and gender, and outputs the skeletal (bone) age. The intervention involves using this tool as a factor in the clinical decision making process of the participating radiologists. The radiologist's decision will be considered final.
Study: NCT04013139

Intervention type: DIAGNOSTIC_TEST
Intervention: CPET
Description: CPET

Intervention type: DIAGNOSTIC_TEST
Intervention: CPET
Description: CPET
Study: NCT02803489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medical device intervention
Study: NCT01220622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: Administration of nimodipine 30mg tid for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo 30mg tid for 6 months
Study: NCT05157854

Intervention type: BEHAVIORAL
Intervention: Active in My Home (AiMH)
Description: AiMH starts with two workshops for staff to introduce them to the intervention and the contributions expected from them. Their task is to participate in a couple of the sessions, inspire the course participant to stick to strategies developed during the sessions and support activity in general between the occupational therapy sessions.~AiMH consists of eight sessions, five individual ones and three in a group. Each session has a theme, such as: activity and health, and is built up with short lessons, using one's senses such as smell or touch, testing a simple activity, and setting goals for an activity one wants to test between sessions. The participants are given around 25 USD to try out that activity.
Study: NCT00838461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02260973

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 (Triglyceride form)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 (Triglyceride form)
Study: NCT03231306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
Study: NCT03903562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: 0.5 mL 9vHPV VLP Vaccine
Study: NCT02591758

Intervention type: DEVICE
Intervention: Hexoskin Vest
Description: The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.

Intervention type: BEHAVIORAL
Intervention: Cardiac rehabilitation program
Description: A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.

Intervention type: OTHER
Intervention: Anxiety assessment as determined by the GAD-7
Description: Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.

Intervention type: OTHER
Intervention: Angina assessment with the angina diary, the SAQ and the SF-36

Intervention type: OTHER
Intervention: Exercise stress test
Description: Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.

Intervention type: OTHER
Intervention: Holter monitoring
Description: 24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
Study: NCT03733041

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: This group will receive rTMS treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: This group will receive sham treatment

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: This group will receive no intervention
Study: NCT04470908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Single oral dose of 320 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: Oral dose of 300 mg once daily
Study: NCT00518986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 200 mg/day
Study: NCT01352442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcuFocus Corneal Inlay ACI 7000PDT
Description: corneal inlay
Study: NCT00811005

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 8-methoxypsoralen or 5- methoxypsoralen
Description: Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet.